Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,699 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenic Disorders Clear all
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

NCT00458211
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Buffalo, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional

Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia

NCT00391677
View directory record Official record
Conditions
Schizophrenia
Interventions
Social skills training with attention shaping procedures, Social skills training without attention shaping
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Monmouth Junction, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Jul 23, 2026, 12:42 PM EDT
Recruiting No phase listed Observational

Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes

NCT04004364
View directory record Official record
Conditions
First Episode Psychosis
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
700 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional Results available

Development of a Mobile System for Self-management of Schizophrenia (SOS)

NCT01969500
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Mobile Application, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436
View directory record Official record
Conditions
Schizophrenia
Interventions
Diet support group, Group counseling and exercise
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

NCT00018837
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorder
Interventions
Community Re-Entry Program: What is Schizophrenia
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional

A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis

NCT01399112
View directory record Official record
Conditions
Smoking, Psychosis
Interventions
Web-based computer program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 23, 2026, 12:42 PM EDT
Terminated Not applicable Interventional Results available

Models of Auditory Hallucination

NCT04210557
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Auditory Hallucination
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCT02675530
View directory record Official record
Conditions
Schizophrenia
Interventions
ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Jul 23, 2026, 12:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings

NCT00001921
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 12:42 PM EDT
Terminated Not applicable Interventional Results available

Metformin for Weight Loss in Schizophrenia

NCT01177709
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Metformin
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 4 Interventional

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

NCT00418171
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
San Bernardino, California • ‘Aiea, Hawaii • Schaumburg, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2009 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional

Neurocognition After Perturbed Sleep

NCT05032963
View directory record Official record
Conditions
Schizophrenia
Interventions
Overnight polysomnography examinations
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

NCT01009047
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone extended release (ER), Aripiprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Dothan, Alabama • Santa Ana, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Youth to Text or Telehealth for Engagement in HIV Care

NCT03681145
View directory record Official record
Conditions
HIV/AIDS, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Depression, Substance Use
Interventions
Counselor delivered telehealth intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Not applicable Interventional

Health Promotion and Fitness for Younger and Older Adults With SMI

NCT02090335
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
In SHAPE, Fitness Club Membership
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 23, 2026, 12:42 PM EDT
Withdrawn Phase 2 Interventional

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

NCT00425815
View directory record Official record
Conditions
Schizophrenia
Interventions
Org 24448, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Jul 23, 2026, 12:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

NCT03077347
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 1 Interventional

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

NCT04127058
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Iloperidone
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jul 23, 2026, 12:42 PM EDT
Terminated Phase 3 Interventional

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, risperidone
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 23, 2026, 12:42 PM EDT
Completed Phase 2 Interventional Results available

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NCT01175135
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-02545920, Placebo, Risperidone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jul 23, 2026, 12:42 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCT07363577
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 12:42 PM EDT